TQB2618

Overview

TQB2618 is an investigational anti-TIM-3 monoclonal antibody targeting HAVCR2 (TIM-3), a compensatory checkpoint receptor on exhausted T cells. It is evaluated alone and in combination with penpulimab in nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• TQB2618 TIM-3 inhibitor ± penpulimab in R/M NPC (NCT05563480, n=17): ORR 0%; median PFS 1.6 months — limited single-agent and combination efficacy observed PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.